中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (8): 1795-1801.doi: 10.4103/1673-5374.361532

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

死亡相关蛋白激酶1与重度抑郁认知障碍有关

  

  • 出版日期:2023-08-15 发布日期:2023-02-24
  • 基金资助:
    河南省科学技术厅项目(192102310084,222102310143);郑州大学基础医学院青年基金项目(JCYXY2017-YQ-07)

Death-associated protein kinase 1 is associated with cognitive dysfunction in major depressive disorder

Xiao-Hui Li1, #, Hong-Can Zhu2, #, Xue-Min Cui1, 3, Wang Wang1, 3, Lin Yang1, 3, Li-Bo Wang4, Neng-Wei Hu1, Dong-Xiao Duan1, *   

  1. 1Department of Physiology and Neurobiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province, China; 2Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China; 3Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province, China; 4Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
  • Online:2023-08-15 Published:2023-02-24
  • Contact: Dong-Xiao Duan, PhD, dongxiaoduan@zzu.edu.cn.
  • Supported by:
    This study was supported by the Department of Science and Technology of Henan Province, Nos. 192102310084 (to HCZ), 222102310143 (to DXD); and the Youth Fund of School of Basic Medical Sciences of Zhengzhou University, No. JCYXY2017-YQ-07 (to DXD).

摘要:

作者既往研究发现,重度抑郁小鼠模型海马组织中死亡相关蛋白激酶1表达增加,而死亡相关蛋白激酶1与阿尔茨海默症认知功能障碍有关,且抑郁是阿尔茨海默症的高危诱发因素和前期临床表现,因此推测死亡相关蛋白激酶1的可能与重度抑郁认知功能障碍有关。为此,实验以社会孤立和慢性压力刺激方法制备了重度抑郁小鼠模型,发现其海马CA3区中死亡相关蛋白激酶1和tau蛋白水平增加,且tau蛋白在Thr231、Ser262和Ser396残基处发生磷酸化,神经元中死亡相关蛋白激酶1从神经元轴突表达较多,转变为细胞膜和胞浆的过表达。经运动和抗抑郁药物西酞普兰治疗后,重度抑郁小鼠模型海马中死亡相关蛋白激酶1表达以及tau蛋白磷酸化减少,且抑郁症状和认知功能障碍明显减轻。因而,死亡相关蛋白激酶1可能是重度抑郁与认知功能障碍的潜在干预靶点。

https://orcid.org/0000-0002-9823-6753 (Dong-Xiao Duan)

关键词: 行为学, 认知功能障碍, 重度抑郁, 死亡相关蛋白激酶1, 阿尔茨海默病, 海马, tau蛋白, 磷酸化, 运动, 抗抑郁药物

Abstract: We previously showed that death-associated protein kinase 1 (DAPK1) expression is increased in hippocampal tissue in a mouse model of major depressive disorde and is related to cognitive dysfunction in Alzheimer’s disease. In addition, depression is a risk factor for developing Alzheimer’s disease, as well as an early clinical manifestation of Alzheimer’s disease. Meanwhile, cognitive dysfunction is a distinctive feature of major depressive disorder. Therefore, DAPK1 may be related to cognitive dysfunction in major depressive disorder. In this study, we established a mouse model of major depressive disorder by housing mice individually and exposing them to chronic, mild, unpredictable stressors. We found that DAPK1 and tau protein levels were increased in the hippocampal CA3 area, and tau was hyperphosphorylated at Thr231, Ser262, and Ser396 in these mice. Furthermore, DAPK1 shifted from axonal expression to overexpression on the cell membrane. Exercise and treatment with the antidepressant drug citalopram decreased DAPK1 expression and tau protein phosphorylation in hippocampal tissue and improved both depressive symptoms and cognitive dysfunction. These results indicate that DAPK1 may be a potential reason and therapeutic target of cognitive dysfunction in major depressive disorder. 

Key words: Alzheimer’s disease, antidepressant drug, behavioral tests, cognitive dysfunction, death-associated protein kinase 1, exercise, hippocampus, major depressive disorder, phosphorylation, tau protein